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Abstract 
A 78-year-old male who experienced multiple recurrences of hepatocellular carcinoma 
(HCC) with hepatitis C virus (HCV)-related cirrhosis underwent transcatheter arterial 
chemoembolization and ablation and survived for more than 10 years. His serum HCV 
RNA level was 2.8 log IU/ml and the serotype of HCV was 2. He underwent long-term 
super-low-dose (20 μg/week) pegylated interferon-alpha 2b therapy to prevent 
recurrence of HCC. He became negative for HCV RNA 2 months later, and thereafter 
remained negative after the discontinuation of interferon therapy, and has not 
experienced a recurrence of HCC for more than 20 months. 
Introduction 
The main cause of death in patients with chronic hepatitis C is hepatocellular 
carcinoma (HCC) [1–4]. Moreover, HCC complicated with hepatitis C virus (HCV)-
related chronic hepatitis or cirrhosis recurs frequently after curative therapies for the 
initial HCC [5]. Treatment has traditionally focused on curing only the recurrent HCC. 
Nevertheless, recent studies on the efficacy of interferon (IFN) in the prevention of 
recurrence of HCC and survival after curative resection of the HCC in patients with HCV 
cirrhosis have provided conflicting data [6–15]. Moreover, the Japanese Guidelines (The 
Study Group for the Standardization of Treatment of Viral Hepatitis Including Cirrhosis, 
Ministry of Health, Labour and Welfare of Japan) stated that long-term IFN therapy  
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should be considered for patients with compensated cirrhosis in order to prevent HCC in 
2008 [16]. Arase et al. recently reported that long-term IFN monotherapy using a low 
dose of natural IFN-alpha was effective for preventing hepatocarcinogenesis in elderly 
patients with chronic hepatitis C [17]. No case report has so far documented the 
prevention of future HCC recurrence by the long-term use of low-dose pegylated IFN 
(Peg-IFN). This report presents a case of HCV associated with cirrhosis with a sustained 
prevention of HCC recurrence by long-term administration of super-low-dose 
Peg-IFN-alpha 2b. 
Case Report 
A 78-year-old male was diagnosed to have HCV infection and HCC in the right lobe of the liver in 
1997. He had a sufficient hepatic reserve and underwent partial hepatectomy for the first HCC. His liver 
function was monitored and periodically checked for recurrent HCC by blood tests and computed 
tomography. Unfortunately, recurrence of HCC occurred in 2002, 5 years after the resection. A solitary 
tumor was detected in S7 of the liver, which was treated by percutaneous microwave coagulation 
therapy. The clinical course is shown figure 1. Subsequent treatment of recurrence in both lobes with 
transarterial lipiodol chemoembolization (TACE) was performed on six occasions (2003, 2006, 2007, 
2008, 2008 and 2009) and by the combination treatment of TACE and radiofrequency ablation in 2005, 
with clinical, analytical and imaging follow-up studies. The repeated intravascular chemoembolization 
caused severe vascular injury. The right hepatic artery became completely obstructed. Moreover, a 
narrow neovascularity from the gastroduodenal artery formed a collateral artery. Similarly, the left 
hepatic artery was strongly damaged and narrowed (fig. 2). Intravascular chemoembolization would 
have been difficult to perform after the last TACE in February 2009. 
The Japanese Guidelines recommend that long-term IFN therapy should be considered for 
preventing HCC in patients with HCV-related cirrhosis [16]. However, IFN is expensive and has a 
number of serious side effects. Adverse events have a tendency to occur in elderly patients [18, 19]. 
Therefore, physicians often avoid IFN therapy in elderly patients because of side effects [20]. This was 
the situation in the current case. His serum HCV RNA level was 2.8 log IU/ml and serotype of HCV was 
2. He was very concerned about the side effects of standard IFN. Therefore, he was treated with 
Peg-IFN, because standard IFN might have a more negative effect on his quality of life than Peg-IFN. 
Moreover, a previous paper reported that patients with low HCV RNA levels tend to eradicate HCV 
RNA with a low dose of IFN [21]. Therefore, super-low-dose Peg-IFN therapy (Peg-IFN-alpha 2b, 
20 μg/week) was started in February 2009 after providing the patient with detailed information 
regarding his condition and treatment, and after gaining his informed consent. Peg-IFN (a total of 
1,240 μg) was administered over an extended period. Serum ALT showed a tendency to decrease after 
Peg-IFN therapy was started, and it has remained within the normal range since March 2009. Moreover, 
HCVRNA has remained negative since April 2009 (fig. 3). No side effects such as flu-like symptoms 
occurred during the Peg-IFN treatment period. The clinical laboratory data are shown in table 1. 
The most common side effect of Peg-IFN therapy is bone marrow suppression with leukopenia, 
thrombocytopenia and anemia. He did not have to withdraw the treatment due to this Peg-IFN side 
effect throughout this treatment. Moreover, this treatment had little effect on his daily life. He has been 
free from HCC recurrence for more than 20 months, even though IFN treatment was discontinued. 
Discussion 
Many patients with chronic hepatitis C infection are generally elderly. In addition, the 
age of HCV-related HCC patients has been increasing, with a peak around age 70 [22, 23]. 
Treatment of elderly patients with IFN is problematic. Nevertheless, a study concluded 
that elderly patients with genotype 2a and 2b should receive IFN therapy [20]. Moreover, 
a recent meta-analysis showed that IFN treatment after curative resection or ablation of  
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HCC in HCV-related cirrhotic patients prevents HCC recurrence and improves survival 
[24]. 
IFN therapy reduces the incidence of hepatocarcinogenesis in patients with HCV 
infection who achieve sustained virological response [25]. The inhibitory effect of IFN on 
development of HCC in patients with chronic hepatitis C aged 60 and over is limited to 
patients achieving sustained virological response following 6 months of IFN monotherapy 
[26]. Sustained prevention of HCC recurrence was accomplished when the current 
patient achieving sustained virological response. 
Peg-IFNs have long elimination half-lives and steady serum concentrations that may 
prevent viral rebound between doses and reduce the risk of ‘escape mutants’ [27]. The 
super-low-dose Peg-IFN therapy which was administered to the current case may have 
contributed to the favorable outcome. 
A nonrandomized retrospective study observed the beneficial effect of long-term 
natural IFN-alpha therapy on hepatocarcinogenesis in elderly chronic hepatitis C 
patients. This paper showed that the alpha-fetoprotein (AFP) baseline was decreased after 
initiation of IFN therapy in most patients. Moreover, the cumulative rate of HCC 
development in patients whose serum level of AFP was within normal limits after 
initiation of IFN therapy was lower than that of patients with a high level of AFP despite 
IFN therapy. This paper concluded that AFP was a suitable indicator in long-term IFN 
therapy for protecting against HCC [17]. In this case, the serum level of AFP had 
remained within the normal limits before the last TACE performance. Nevertheless, the 
tumor marker PIVKA II showed a tendency to decrease after Peg-IFN therapy was started 
in the current patient, and it has remained within normal limits. This is very important 
for the sustained prevention of HCC recurrence with Peg-IFN therapy as well. 
The serum level of PIVKA II showed a slow decline to the normal range over 
5 months. A previous paper demonstrated that IFN-alpha potentiated the apoptotic effect 
of TRAIL in human hepatoma cells by regulating the expression of DR5 or survivin and 
by repressing TRAIL-mediated NF-κB activation [28]. This low-dose Peg-IFN therapy 
might induce the death and apoptosis of remaining HCC cells. 
Fortunately, in patients with genotype 2 and low virus load, HCV RNA tends to be 
eradicated with a small dose of IFN [29–32]. Super-low-dose Peg-IFN therapy was 
administered over a long period at the request of our patient. His HCV RNA rapidly 
became negative. Generally, Peg-IFN is expensive and has a number of serious side 
effects. It is thus considered to be preferable to shorten the treatment period. A shorter 
period of Peg-IFN therapy should be considered in future studies. 
In conclusion, this case report indicates that low-dose Peg-IFN administration may 
successfully inhibit hepatitis C-related HCC recurrence of elderly patients. 
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Table 1. Laboratory data of pre-TACE, post-1st, post-4th, post-24th and post-last IFN therapy 
Characteristic  Pre-TACE  Post-1st IFN  Post-4th IFN  Post-24th IFN  Post-last IFN 
HCV-RNA, log IU/ml  2.8  not checked  negative  negative  negative 
AST, IU/l  45  31  21  21  21 
ALT, IU/l  128  37  17  18  15 
PIVKA II, mAU/ml  344  62  64  24  24 
Hemoglobin, g/dl  13.4  14.1  12.9  13.0  12.4 
Platelets, ×10
4/ml 18.2  12.5  13.8  12.1  13.9 
WBC, ml  5,420  4,080  4,980  3,920  4,170 
ALT = Alanine aminotransferase; AST = aspartate aminotransferase; HCV = hepatitis C virus; 
IFN = interferon; TACE = transarterial lipiodol chemoembolization; WBC = white blood cell count. 
Normal reference ranges under 40 mAU/ml for PIVKA II, 5–45 IU/l for ALT, 10–40 IU/l for AST. 
 
 
 
 
 
Fig. 1. Clinical course of the initial and recurrent HCC treatment. TACE = Transarterial lipiodol 
chemoembolization; PMCT = percutaneous microwave coagulation therapy; RFA = radiofrequency 
ablation. 
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Fig. 2. Celiac arteriogram of last TACE showed severe vascular injury. The right hepatic artery had 
become completely obstructed. Moreover, a narrow neovascularity from the gastroduodenal artery 
formed a collateral artery. The left hepatic artery was severely damaged and narrowed. 
 
 
 
Fig. 3. Clinical course of super-low-dose Peg-IFN-alpha 2b therapy (20 μg/week, total 1,240 μg, 
16 months). Starting month: February 2009. 
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